Development of cancer Immunotherapy targeting BTLA

• Project/Area Number: 23800043
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Single-year Grants
• Research Field: Tumor immunology
• Research Institution: Yamaguchi University
• Principal Investigator: TAMADA Koji 山口大学, 大学院・医学系研究科, 教授 (00615841)
• Project Period (FY): 2011 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000); Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: 免疫チェックポイント機構 / 免疫共シグナル分子 / 腫瘍反応性 T リンパ球 / がん免疫療法 / 共シグナル分子 / ＢＴＬＡ / ＨＶＥＭ / 腫瘍免疫学 / BTLA / HVEM

Research Abstract

This project aims at optimized regulation of immune co-signal functions so as to induce potent anti-tumor immunotherapy. For this purpose, we have generated a fusion protein consisting extracellular domain of BTLA and immunoglobulin Fc region, which could deliver stimulatory co-signal while attenuating inhibitory co-signal simultaneously. Whereas this protein induced T cell activation, its injection led to no apparent anti-tumor effect in animal models. We plan to re-construct this protein in order to increase its immune activity and re-examine anti-tumor effects in vivo.

Research Products

• [Journal Article] Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory (2012)
  • Author(s): Kuramasu A
  • Journal Title: Cancer Immunology, Immunotherapy Volume: 61 Issue: 2 Pages: 203-214
  • DOI: 10.1007/s00262-011-1101-8
  • Peer Reviewed
• [Journal Article] Redirecting gene-modified T cells toward various cancer types using tagged antibodies (2012)
  • Author(s): Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Davila E
  • Journal Title: Clin Cancer Res Volume: 18 Issue: 23 Pages: 6436-6445
  • DOI: 10.1158/1078-0432.ccr-12-1449
  • Peer Reviewed
• [Presentation] Redirecting gene-modified T cells toward various cancer types using tagged antibodies (2013)
  • Author(s): Yukimi Sakoda, Koji Tamada
  • Organizer: Keystone Symposia: Cancer Immunotherapy and Immunology
  • Place of Presentation: Vancouver、Canada
• [Presentation] Redirecting gene-modified T cells toward various cancer types using tagged antibodies (2013)
  • Author(s): Yukimi Sakoda, Koji Tamada
  • Organizer: Keystone Synposia: Cancer Immunology and Immunotherapy
  • Place of Presentation: Vancouver, Canada
• [Presentation] Recent Advances in Immunology: What we have learned and what we can do. (2012)
  • Author(s): Koji Tamada
  • Organizer: 2nd Bulgarian-Japanese symposium
  • Place of Presentation: Sofia、Bulgaria
  • Year and Date: 2012-12-08
• [Presentation] 難治性消化器癌に対する革新的免疫療法 (2012)
  • Author(s): 玉田耕治
  • Organizer: 第20回消化器関連学会習慣
  • Place of Presentation: 神戸国際会議場(神戸)
• [Presentation] 標識抗原を認識する新規キメラ抗原受容体を利用したがん免疫療法 (2012)
  • Author(s): 佐古田幸美、玉田耕治
  • Organizer: 日本がん免疫学会
  • Place of Presentation: 北海道大学(札幌)
• [Presentation] 標識抗原を認識する新規キメラ抗原受容体を利用したがん免疫療法 (2012)
  • Author(s): 佐古田幸美、玉田耕治
  • Organizer: 第１６回がん免疫学会
  • Place of Presentation: 北海道大学学術交流会館（札幌）
• [Presentation] 難治性消化器癌に対する革新的免疫療法 (2012)
  • Author(s): 玉田耕治
  • Organizer: 第２０回消化器関連学会週間
  • Place of Presentation: 神戸国際会議場（神戸）
  • Invited
• [Presentation] Recent Advances in Immunology: What we have learned and what we can do (2012)
  • Author(s): Koji Tamada
  • Organizer: 2nd Bulgarian-Japanese Symposium
  • Place of Presentation: Sofia, Bulgaria
  • Invited
• [Book] TNF ファミリー関連分子標的(4-1BB, LIGHT, HVEM)、炎症と免疫 (2013)
  • Author(s): 玉田耕治
  • Publisher: 先端医学社
• [Remarks] ホームページ
  • URL: http://ds.cc.yamaguchi-u.ac.jp/~plasma/